Table 2 Baseline demographic and clinical characteristics (postmatching)
Responders (n = 2337) | Nonresponders (n = 2337) | p Valuea | Standardized differenceb | |
|---|---|---|---|---|
Female sex, n (%) | 1655 (70.8%) | 1659 (71.0%) | 0.900 | 0.00 |
Age at index date, years, mean (SD) | 52.3 (11.30) | 52.0 (10.66) | 0.466 | 0.02 |
Geographic region, n (%) | ||||
Northeast | 348 (14.9%) | 327 (14.0%) | 0.382 | 0.03 |
South | 689 (29.5%) | 609 (26.1%) | 0.009 | 0.08 |
Midwest | 731 (31.3%) | 786 (33.6%) | 0.086 | 0.05 |
West | 453 (19.4%) | 493 (21.1%) | 0.145 | 0.04 |
Unknown | 116 (5.0%) | 122 (5.2%) | 0.690 | 0.01 |
Health plan type, n (%) | ||||
HMO | 590 (25.2%) | 546 (23.4%) | 0.133 | 0.04 |
PPO | 1604 (68.6%) | 1642 (70.3%) | 0.228 | 0.04 |
CDHP | 143 (6.1%) | 149 (6.4%) | 0.717 | 0.01 |
Any Medicare plan (Medicare Advantage or Medicare Supplemental plus Part D), n (%) | 182 (7.8%) | 182 (7.8%) | 1.000 | 0.00 |
TNFi agent on index fill, n (%) | ||||
Adalimumab | 586 (25.1%) | 579 (24.8%) | 0.813 | 0.01 |
Certolizumab pegol | 24 (1.0%) | 43 (1.8%) | 0.019 | 0.07 |
Etanercept | 1418 (60.7%) | 1418 (60.7%) | 1.000 | 0.00 |
Golimumab | 56 (2.4%) | 43 (1.8%) | 0.187 | 0.04 |
Infliximab | 253 (10.8%) | 254 (10.9%) | 0.962 | 0.00 |
Prescribing physician specialty on index TNFi claim, n (%) | ||||
Rheumatology | 1872 (80.1%) | 1864 (79.8%) | 0.770 | 0.01 |
PCPc | 35 (1.5%) | 38 (1.6%) | 0.723 | 0.01 |
Other | 47 (2.0%) | 40 (1.7%) | 0.449 | 0.02 |
Unknown | 383 (16.4%) | 395 (16.9%) | 0.637 | 0.01 |
QCI, mean (SD) | 1.5 (1.03) | 1.5 (0.99) | 0.977 | 0.00 |
CIRAS, mean (SD) | 6.6 (1.73) | 6.5 (1.68) | 0.043 | 0.02 |
Targeted comorbidities of interest, n (%) | ||||
Chronic respiratory/pulmonary conditions | 305 (13.1%) | 365 (15.6%) | 0.012 | 0.07 |
CVDd | 197 (8.4%) | 206 (8.8%) | 0.592 | 0.02 |
Diabetes | 280 (12.0%) | 250 (10.7%) | 0.166 | 0.04 |
Dyslipidemia | 789 (33.8%) | 771 (33.0%) | 0.577 | 0.02 |
Fibromyalgia | 316 (13.5%) | 392 (16.8%) | 0.002 | 0.09 |
Fragility fractures (closed) | 34 (1.5%) | 37 (1.6%) | 0.720 | 0.01 |
GI ulcer | 23 (1.0%) | 26 (1.1%) | 0.667 | 0.01 |
Hypertension | 809 (34.6%) | 880 (37.7%) | 0.031 | 0.06 |
Low-back pain | 461 (19.7%) | 594 (25.4%) | <0.001 | 0.14 |
Mental health issues | 476 (20.4%) | 471 (20.2%) | 0.856 | 0.01 |
Osteoarthritis | 892 (38.2%) | 969 (41.5%) | 0.021 | 0.07 |
Osteoporosis | 231 (9.9%) | 254 (10.9%) | 0.270 | 0.03 |